JP2020031642A5 - - Google Patents

Download PDF

Info

Publication number
JP2020031642A5
JP2020031642A5 JP2019187371A JP2019187371A JP2020031642A5 JP 2020031642 A5 JP2020031642 A5 JP 2020031642A5 JP 2019187371 A JP2019187371 A JP 2019187371A JP 2019187371 A JP2019187371 A JP 2019187371A JP 2020031642 A5 JP2020031642 A5 JP 2020031642A5
Authority
JP
Japan
Prior art keywords
fam13c
klk2
srd5a2
azgp1
rna transcripts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019187371A
Other languages
English (en)
Japanese (ja)
Other versions
JP7042784B2 (ja
JP2020031642A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020031642A publication Critical patent/JP2020031642A/ja
Publication of JP2020031642A5 publication Critical patent/JP2020031642A5/ja
Priority to JP2021187716A priority Critical patent/JP2022031750A/ja
Application granted granted Critical
Publication of JP7042784B2 publication Critical patent/JP7042784B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019187371A 2010-07-27 2019-10-11 遺伝子発現を用いた前立腺癌の予後を定量化する方法 Expired - Fee Related JP7042784B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021187716A JP2022031750A (ja) 2010-07-27 2021-11-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US36821710P 2010-07-27 2010-07-27
US61/368,217 2010-07-27
US41431010P 2010-11-16 2010-11-16
US61/414,310 2010-11-16
US201161485536P 2011-05-12 2011-05-12
US61/485,536 2011-05-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017219711A Division JP2018068299A (ja) 2010-07-27 2017-11-15 遺伝子発現を用いた前立腺癌の予後を定量化する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021187716A Division JP2022031750A (ja) 2010-07-27 2021-11-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法

Publications (3)

Publication Number Publication Date
JP2020031642A JP2020031642A (ja) 2020-03-05
JP2020031642A5 true JP2020031642A5 (cg-RX-API-DMAC7.html) 2020-05-07
JP7042784B2 JP7042784B2 (ja) 2022-03-28

Family

ID=45527113

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013521883A Pending JP2013532482A (ja) 2010-07-27 2011-07-25 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2016028850A Expired - Fee Related JP6246845B2 (ja) 2010-07-27 2016-02-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2017219711A Pending JP2018068299A (ja) 2010-07-27 2017-11-15 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2019187371A Expired - Fee Related JP7042784B2 (ja) 2010-07-27 2019-10-11 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2021187716A Pending JP2022031750A (ja) 2010-07-27 2021-11-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2013521883A Pending JP2013532482A (ja) 2010-07-27 2011-07-25 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2016028850A Expired - Fee Related JP6246845B2 (ja) 2010-07-27 2016-02-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2017219711A Pending JP2018068299A (ja) 2010-07-27 2017-11-15 遺伝子発現を用いた前立腺癌の予後を定量化する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021187716A Pending JP2022031750A (ja) 2010-07-27 2021-11-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法

Country Status (12)

Country Link
US (6) US20120028264A1 (cg-RX-API-DMAC7.html)
EP (5) EP3556870B9 (cg-RX-API-DMAC7.html)
JP (5) JP2013532482A (cg-RX-API-DMAC7.html)
AU (1) AU2011282892B2 (cg-RX-API-DMAC7.html)
CA (2) CA3081061C (cg-RX-API-DMAC7.html)
DK (3) DK2598659T3 (cg-RX-API-DMAC7.html)
ES (4) ES2611000T3 (cg-RX-API-DMAC7.html)
IL (5) IL243203A (cg-RX-API-DMAC7.html)
MX (4) MX359416B (cg-RX-API-DMAC7.html)
NZ (1) NZ607282A (cg-RX-API-DMAC7.html)
SG (3) SG10201505769PA (cg-RX-API-DMAC7.html)
WO (1) WO2012015765A2 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007350331A1 (en) * 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
HK1201881A1 (en) * 2012-01-31 2015-09-11 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
TW201343920A (zh) * 2012-03-29 2013-11-01 Nat Health Research Institutes 預測前列腺癌預後之分子標記、方法與套組
BR102012007246A2 (pt) * 2012-03-30 2016-02-10 Fundação Antonio Prudente métodos para prognóstico e classificação de resultados de um evento
US20150104440A1 (en) * 2012-04-12 2015-04-16 Cornell University MiRNA-31 AS A DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC AGENT IN CANCER
GB201207722D0 (en) 2012-05-02 2012-06-13 Bergenbio As Method
WO2014012176A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer
CN102816862A (zh) * 2012-09-19 2012-12-12 南开大学 miRNA 222在前列腺癌血清学诊断试剂盒中的应用
WO2014071226A1 (en) * 2012-11-02 2014-05-08 The Regents Of The University Of California Methods and systems for determining a likelihood of adverse prostate cancer pathology
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
EP3090265B1 (en) * 2013-12-30 2020-04-08 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
JP6666852B2 (ja) * 2014-01-16 2020-03-18 イルミナ インコーポレイテッド 前立腺がん再発の予後に関する遺伝子発現パネル
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10801072B2 (en) 2014-09-04 2020-10-13 Miodx Method of analysis allowing avoidance of surgery
WO2016115312A1 (en) 2015-01-14 2016-07-21 Ohio State Innovation Foundation Mirna-based predictive models for diagnosis and prognosis of prostate cancer
EP3256602B1 (en) 2015-02-11 2019-09-04 QIAGEN GmbH A microrna-based method for early detection of prostate cancer in urine samples
WO2016134727A1 (en) 2015-02-27 2016-09-01 Exiqon A/S A microrna-based method for assessing the prognosis of a prostate cancer patient
CN104880565A (zh) * 2015-05-04 2015-09-02 贵州省人民医院 Zfp36前列腺癌预后诊断的检测试剂及其试剂盒
JP6743056B2 (ja) * 2015-05-29 2020-08-19 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 前立腺がん予後判定の方法
US20170107580A1 (en) 2015-10-15 2017-04-20 Dendreon Pharmaceuticals, Inc. Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t
WO2017127696A1 (en) 2016-01-20 2017-07-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
SG11201806609TA (en) 2016-02-02 2018-09-27 Guardant Health Inc Cancer evolution detection and diagnostic
WO2017210662A1 (en) * 2016-06-03 2017-12-07 Castle Biosciences, Inc. Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma
US10724089B2 (en) 2016-10-06 2020-07-28 The Board Of Trustees Of The University Of Illinois Spatial molecular analysis of tissue
WO2018098241A1 (en) * 2016-11-22 2018-05-31 University Of Rochester Methods of assessing risk of recurrent prostate cancer
GB201619808D0 (en) * 2016-11-23 2017-01-04 Univ London Queen Mary Biomarkers for the prognosis and diagnosis of cancer
WO2019145483A1 (en) * 2018-01-25 2019-08-01 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer
CA3091647A1 (en) * 2018-02-22 2019-08-29 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
WO2020214718A1 (en) * 2019-04-16 2020-10-22 Memorial Sloan Kettering Cancer Center Rrm2 signature genes as prognostic markers in prostate cancer patients
JP2020195314A (ja) * 2019-05-31 2020-12-10 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
JP7762135B2 (ja) * 2019-07-05 2025-10-29 インテレクソン・ゲーエムベーハー 個人のhlaパターンの決定、予後因子としての使用、標的遺伝子、及び治療薬
WO2021124455A1 (ja) * 2019-12-17 2021-06-24 株式会社 東芝 分析方法及びキット
EP4077667A1 (en) * 2019-12-19 2022-10-26 F. Hoffmann-La Roche AG Use of sept9 inhibitors for treating hepatitis b virus infection
CN115038969A (zh) * 2020-01-30 2022-09-09 阿罗塞尔公司 预测患者生存
EP3885453A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on dna repair genes
US11845993B2 (en) * 2020-03-24 2023-12-19 The Regents Of The University Of Michigan Methods for identifying prostate cancer
CA3186853A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
ES1277194Y (es) 2021-03-25 2021-11-26 Keyzell Holding Sl Sistema basado en inteligencia artificial para analizar biomarcadores y personalizar tratamientos para cáncer
JPWO2024162265A1 (cg-RX-API-DMAC7.html) 2023-01-30 2024-08-08
CN116640734B (zh) * 2023-06-17 2025-01-24 青岛农业大学 关键基因在体外调控卵母细胞gvbd的用途及干扰片段

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6012696A (en) 1995-06-14 1997-01-15 Aberdeen University Prognostic and therapeutic system for cancer
US6300060B1 (en) 1995-11-09 2001-10-09 Dana-Farber Cancer Institute, Inc. Method for predicting the risk of prostate cancer morbidity and mortality
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
US5712097A (en) 1996-01-19 1998-01-27 The Johns Hopkins University School Of Medicine Tumor suppressor gene, DPC4
WO1998002748A1 (en) 1996-07-15 1998-01-22 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6190857B1 (en) 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
AU8403098A (en) 1997-07-15 1999-02-10 Deaconess Hospital Reagents and methods for diagnosis and prognosis of proliferative disor ders
US20030096742A1 (en) 1997-12-03 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
EP1084273A1 (en) 1998-06-06 2001-03-21 Genostic Pharma Limited Probes used for genetic profiling
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
WO2001051635A2 (en) * 2000-01-13 2001-07-19 Genentech, Inc. Novel stra6 polypeptides
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
JP4495349B2 (ja) * 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド 癌の遺伝マーカーを生物学的サンプルにおいて検出するための核酸配列
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
WO2000061744A1 (fr) 1999-04-09 2000-10-19 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux genes de foetus
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
GB9926805D0 (en) 1999-11-13 2000-01-12 Zeneca Ltd Diagnostic methods
US6448086B1 (en) 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
US6566130B1 (en) 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
AU2002216009A1 (en) 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
WO2002074156A2 (en) 2001-02-02 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002079411A2 (en) 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
US20040203012A1 (en) 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
US20030138793A1 (en) 2001-06-10 2003-07-24 Irm Llc, A Delaware Limited Liability Company Molecular signatures of commonly fatal carcinomas
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
KR20040064275A (ko) 2001-11-09 2004-07-16 소스 프리시전 메디슨, 인코포레이티드 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인
WO2003050243A2 (en) 2001-12-10 2003-06-19 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
US6949342B2 (en) 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
US20030215835A1 (en) 2002-01-15 2003-11-20 Zairen Sun Differentially-regulated prostate cancer genes
CA2478572A1 (fr) 2002-03-14 2003-09-18 Fanny Coignard Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
AUPS187002A0 (en) * 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
CA2498418A1 (en) 2002-09-10 2004-03-25 Guennadi V. Glinskii Gene segregation and biological sample classification methods
WO2004028346A2 (en) 2002-09-25 2004-04-08 Amersham Biosciences (Sv) Corp. Detection methods
AU2003302777A1 (en) 2002-12-05 2004-06-30 Regulome Corporation Profiled regulatory sites useful for gene control
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
WO2004077942A2 (en) 2003-02-28 2004-09-16 Genpath Pharmaceuticals, Incorporated Inducible prostate cancer model
US20070059697A1 (en) 2003-04-15 2007-03-15 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
WO2004108896A2 (en) * 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
CA2530738C (en) 2003-06-24 2020-01-21 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
DK1644858T3 (da) * 2003-07-10 2018-01-22 Genomic Health Inc Funktionel beklædning med mindst et yderlag og en indermembran.
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
JP2007507204A (ja) 2003-07-29 2007-03-29 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼモデュレーションのバイオマーカー
AU2004298604B2 (en) 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
WO2005068664A2 (en) 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression
GB0400976D0 (en) 2004-01-16 2004-02-18 Univ Cambridge Tech Methods of diagnosis
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
WO2005083128A2 (en) 2004-02-25 2005-09-09 University Of South Florida Methods for predicting cancer outcome and gene signatures for use therein
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
WO2005111619A1 (en) 2004-04-29 2005-11-24 Marc Ramael Method and kit for detecting components in a sample
EP2383350B1 (en) 2004-05-07 2018-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
CN101023185A (zh) 2004-05-27 2007-08-22 威特克斯医药股份有限公司 用于监测impdh通路抑制作用的生物学标记
EP1756309A2 (en) 2004-06-03 2007-02-28 Bayer HealthCare AG Methods for predicting and monitoring response to cancer therapy
WO2006005043A2 (en) 2004-06-30 2006-01-12 Cemines, Inc. Compositions and methods for detecting protein interactions with target dna sequences
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
CN102680686A (zh) 2004-08-13 2012-09-19 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
DK1836629T3 (da) * 2004-11-05 2020-05-18 Genomic Health Inc Forudsigelse af respons på kemoterapi ved anvendelse af markører for genekspression
US20100143247A1 (en) 2004-11-24 2010-06-10 St. George's Enterprises Limited Diagnosis of prostate cancer
WO2006066240A2 (en) 2004-12-17 2006-06-22 Veridex Llc Methods for assessing patients with acute myeloid leukemia
US7943306B2 (en) 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
CA2595699A1 (en) 2005-02-17 2006-08-24 Dana-Farber Cancer Institute, Inc. Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
WO2006091776A2 (en) * 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
EP1874471A4 (en) * 2005-03-16 2008-12-10 Sidney Kimmel Cancer Ct METHOD AND COMPOSITIONS FOR PREDICTING DEATH BY CANCER AND SURVIVAL OF PROSTATE CANCER USING GENE EXPRESSION SIGNATURES
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
WO2006113678A2 (en) 2005-04-15 2006-10-26 Oncomethylome Sciences, Inc. Methylation markers for diagnosis and treatment of cancers
US20080275652A1 (en) 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20060292610A1 (en) 2005-06-06 2006-12-28 Regents Of The University Of Michigan Prognostic meta signatures and uses thereof
EP1899486A4 (en) 2005-06-08 2009-07-22 Millennium Pharm Inc METHOD FOR IDENTIFYING, ASSESSING AND TREATING PATIENTS IN CANCER THERAPY
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7718369B2 (en) * 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
JP2009514555A (ja) 2005-11-08 2009-04-09 ユークリッド ダイアグノスティックス リミテッド ライアビリティー カンパニー 癌評価の遺伝子関連CpGアイランドのメチル化アッセイのための材料と方法
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CN101326292A (zh) 2005-12-08 2008-12-17 诺瓦提斯公司 Fgfr3抑制物对基因转录的影响
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
WO2007075672A2 (en) 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
DK1974058T3 (da) 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
ES2300176B1 (es) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US20070218512A1 (en) 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
US20090098538A1 (en) 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
WO2007140352A2 (en) 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers
WO2007149965A2 (en) 2006-06-22 2007-12-27 Wisconsin Alumni Research Foundation Stromal collagen in the diagnosis and characterization of breast cancer
US20100330602A1 (en) 2006-09-19 2010-12-30 Emory University Use of Soluble Galectin-3 (Gal-3) for Cancer Treatment
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
WO2008048570A2 (en) 2006-10-16 2008-04-24 The Ohio State University Research Foundation Piwil2-related biomarkers and cell lines useful therewith
WO2008067065A2 (en) * 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
WO2008061104A2 (en) 2006-11-13 2008-05-22 Invitrogen Corporation Methods and kits for detecting prostate cancer biomarkers
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
EP2099929A4 (en) 2006-12-06 2010-12-08 Avalon Pharmaceuticals ASSOCIATED WITH CANCER GENES AS A BIOMARKER TO MONITOR THE RESPONSE TO IMPDH INHIBITORS
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
US20100120788A1 (en) 2007-01-09 2010-05-13 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
US20090047694A1 (en) 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
US20090258795A1 (en) 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2008122447A2 (en) 2007-04-10 2008-10-16 Epigenomics Ag Dna methylation assay for the diagnosis or prognosis of medical conditions
US20110091377A1 (en) 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
EP2068618A4 (en) 2007-05-21 2011-01-19 Dana Farber Cancer Inst Inc COMPOSITIONS AND METHODS OF DISCOVERING TUMOR GENES
US20110136123A1 (en) 2007-08-15 2011-06-09 Universite De Sherbrooke Alternative splicing gene variants in cancer
WO2009049966A2 (en) 2007-09-07 2009-04-23 Universite Libre De Bruxelles Methods and tools for prognosis of cancer in her2+ patients
WO2009051734A1 (en) 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
GB0721605D0 (en) 2007-11-02 2007-12-12 Cancer Rec Tech Ltd Prostrate cancer susceptibility screening
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
WO2009070767A2 (en) 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
EP2065474A1 (en) 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
EP2215251A2 (en) 2007-11-30 2010-08-11 Siemens Healthcare Diagnostics GmbH Method for predicting therapy responsiveness in basal like tumors
WO2009089521A2 (en) 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
WO2009105154A2 (en) 2008-02-19 2009-08-27 The Jackson Laboratory Diagnostic and prognostic methods for cancer
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP2274699A4 (en) 2008-03-26 2011-04-27 Theranos Inc METHOD AND SYSTEMS FOR EVALUATING CLINICAL RESULTS
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US20110053804A1 (en) 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
EP2288722B1 (en) 2008-04-10 2014-11-05 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
CA2722424A1 (en) 2008-04-25 2009-10-29 Integrated Bioscience Solutions, Llc Cytological methods for detecting cancer
US8093000B2 (en) 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
CA2724433A1 (en) 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
CN102099491A (zh) 2008-05-15 2011-06-15 北卡罗来纳-查佩尔山大学 调节血管生成的新靶标
WO2009140741A1 (en) 2008-05-23 2009-11-26 The University Of Queensland Agents and methods for diagnosing the presence or risk of prostate cancer
US20110136683A1 (en) 2008-05-28 2011-06-09 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
GB0809689D0 (en) 2008-05-28 2008-07-02 Cancer Res Inst Royal Markers for prostate cancee
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
WO2009149166A2 (en) 2008-06-03 2009-12-10 Children's Hospital Medical Center Methods and compositions for the diagnosis and treatment of proliferative disorders
RU2011101378A (ru) 2008-06-16 2012-07-27 Сайвидон Дайагностикс Гмбх (De) Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии
AU2009268659A1 (en) 2008-07-08 2010-01-14 Genomic Health, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
AU2009270851A1 (en) 2008-07-16 2010-01-21 Dana-Farber Cancer Institute, Inc. Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof
NZ590993A (en) 2008-07-21 2012-11-30 Translational Genomics Res Inst Dual specificity phosphatase 1 protein (DUSP1) for diagnosis and prognosis of skin cancer
AU2009291203B2 (en) 2008-09-10 2015-01-22 Life & Brain Gmbh Peripheral zone tumor cells, methods for their preparation and use
JP5819728B2 (ja) 2008-10-20 2015-11-24 ファーマテスト・サービシーズ・オサケユキテュアPharmatest Services Oy Nav3の遺伝子異常および複数遺伝子の異常発現を含む方法および使用
AU2009307651A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Prostate stem cells and uses thereof
CN102308004A (zh) 2008-10-30 2012-01-04 卡里斯生命科学卢森堡控股有限责任公司 评价rna图案的方法
WO2010056993A2 (en) * 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
WO2010056351A2 (en) 2008-11-14 2010-05-20 Stc.Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
GB0821787D0 (en) 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
US20120301887A1 (en) 2009-01-06 2012-11-29 Bankaitis-Davis Danute M Gene Expression Profiling for the Identification, Monitoring, and Treatment of Prostate Cancer
EP2382331B1 (en) 2009-01-07 2016-06-08 Myriad Genetics, Inc. Cancer biomarkers
EP2380025B1 (en) 2009-01-14 2013-09-11 The United States of America, as represented by The Secretary, Department of Health and Human Services Ratio based biomarkers and methods of use thereof
SG172984A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
EP2233590A1 (en) 2009-01-28 2010-09-29 AIT Austrian Institute of Technology GmbH Methylation assay
CA2729593A1 (en) 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-h3 as a biomarker for diagnosing the progression and early lymph node metastasis of cancer
WO2010099577A1 (en) 2009-03-04 2010-09-10 The University Of Queensland Cancer biomarkers and uses therefor
US8554924B2 (en) 2009-03-16 2013-10-08 Apple Inc. Connection to multiple accessories with multiple accessory-specific protocols
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
CN102421920B (zh) 2009-04-16 2015-09-30 加拿大国家研究委员会 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组
EP2241634A1 (en) 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnostic method and tools to predict the effiacy of targeted agents against IGF-1 pathway activation in cancer
WO2010127399A1 (en) 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Gene expression profiles and uses thereof
WO2010129965A1 (en) 2009-05-08 2010-11-11 The Regents Of The University Of California Cancer specific mitotic network
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
JP5773998B2 (ja) 2009-07-08 2015-09-02 ワールドワイド・イノベイティブ・ネットワークWorldwide Innovative Network 患者における薬物の有効性を予測する方法
WO2011039734A2 (en) 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
US20110123990A1 (en) 2009-11-23 2011-05-26 Baker Joffre B Methods To Predict Clinical Outcome Of Cancer
WO2011085263A2 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
WO2014108896A1 (en) 2013-01-08 2014-07-17 Marpe Technologies Ltd. Device and method for body moles mapping and tracking

Similar Documents

Publication Publication Date Title
JP2020031642A5 (cg-RX-API-DMAC7.html)
JP2016174600A5 (cg-RX-API-DMAC7.html)
JP2022031750A5 (cg-RX-API-DMAC7.html)
JP2017055769A5 (cg-RX-API-DMAC7.html)
Turnham et al. The PTEN conundrum: how to target PTEN-deficient prostate cancer
Chang et al. Phenotypic modulation of primary vascular smooth muscle cells by short-term culture on micropatterned substrate
Rossi et al. Conjunctival melanoma: genetic and epigenetic insights of a distinct type of melanoma
Xie et al. MicroRNAs associated with HBV infection and HBV-related HCC
Casarotto et al. Beyond microRNAs: emerging role of other non-coding RNAs in HPV-driven cancers
Ueda et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis
UA110790C2 (uk) Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні
JP2009523028A5 (cg-RX-API-DMAC7.html)
NZ600268A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
JP2016041071A5 (cg-RX-API-DMAC7.html)
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
WO2007143752A3 (en) Targets in breast cancer for prognosis or therapy
HK1213946A1 (zh) 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
Atri et al. MicroRNAs in diagnosis and therapeutics
JP2016521979A5 (cg-RX-API-DMAC7.html)
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
Orlandella et al. Preclinical imaging evaluation of miRNAs’ delivery and effects in breast cancer mouse models: a systematic review
Apanovich et al. Expression Profiles of Genes—Potential Therapy Targets—and Their Relationship to Survival in Renal Cell Carcinoma
JP2015517500A5 (cg-RX-API-DMAC7.html)
CN105506155A (zh) 检测长链非编码rna loc284454表达量的试剂的应用
Ji et al. CircRNA in digestive diseases: recent advances in fundamental mechanism and clinical potential